Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent

Weili Lin, Pratik Mukherjee, Hongyu An, Yingjing Yu, Yi Wang, Katy Vo, Benjamin Lee, Daniel Kido, E. M. Haacke

Research output: Contribution to journalArticlepeer-review

50 Scopus citations

Abstract

Recently, a new imaging method was proposed by Reichenbach et al (Radiology 1997;204:272-277) to image small cerebral venous vessels specifically. This method, referred to as high-resolution blood oxygen level- dependent venography (HRBV), relies on the susceptibility difference between the veins and the brain parenchyma. The resulting phase difference between the vessels and the brain parenchyma leads to signal losses over and above the usual T2* effect. At 1.5 T, a rather long TE (roughly 40 msec) is required for this cancellation to become significant, leading to enhanced susceptibility artifacts and a long data acquisition time. In this study, we examine the utility of incorporating a clinically available T1 reducing contrast agent, Omniscan (Sanofi Winthrop Pharmaceuticals, NY, NY), with the HRBV imaging approach to reduce susceptibility artifacts and imaging time while maintaining the visibility of cerebral veins. Using a double-dose injection of Omniscan, we were able to reduce TE from 40 to 25 msec. This led to a decrease in TR from 57 to 42 msec, allowing a 26% reduction in data acquisition time while maintaining the visibility of cerebral venous vessels and reducing susceptibility artifacts.

Original languageEnglish
Pages (from-to)118-123
Number of pages6
JournalJournal of Magnetic Resonance Imaging
Volume10
Issue number2
DOIs
StatePublished - Aug 1999

Keywords

  • BOLD
  • Contrast agent
  • Venogram

Fingerprint

Dive into the research topics of 'Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent'. Together they form a unique fingerprint.

Cite this